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Background: Neurofibromatosis 1 is one of the most common genetic diseases in humans, presenting with
multiple neurofibromas and an increased risk of various benign and malignant tumors, including breast cancer.
Case presentation: In this paper we report a case of a woman with neurofibromatosis 1 and the challenge
associated with detecting an advanced breast cancer because of numerous skin neurofibromas, which were
responsible for a substantial delay in cancer diagnosis. Literature concerning the association of neurofibromatosis 1
and breast cancer is reviewed and discussed.
Conclusions: Best practice guidelines for breast cancer detection are not sufficient for the screening of
neurofibromatosis 1 carriers. A more intensive clinical and imaging approach should be used if the same early
detection rate as in non-neurofibromatosis 1 women is to be achieved.
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Neurofibromatosis 1 (NF1) is one of the most common
genetic diseases in humans, with a prevalence of one case
in 3,000 births. The disease is caused by mutations in the
NF1 gene, which is considered a classical tumor suppres-
sor [1]. NF1 is an autosomal dominant condition with
complete penetrance but an extremely variable phenotype.
Multiple neurofibromas, café-au-lait spots, “freckling” in
the inguinal and axillary regions and Lisch nodules de-
velop in most affected individuals [1]. Beyond the develop-
ment of neurofibromas, which are benign peripheral nerve
sheath tumors, NF1 patients have an increased risk of de-
veloping other benign and malignant neoplasms, including
gliomas, malignant peripheral nerve sheath tumors
(MPNSTs), juvenile chronic myelomonocytic leukemia,
rhabdomyosarcoma, and pheochromocytoma [2-4]. NF1 is* Correspondence: andre@saudedamama.org
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[5-7].
We report a case of a 54-year-old woman with NF1
and the challenge involved in detecting an advanced
breast cancer because of numerous skin neurofibromas.
We also review the literature concerning the association
between NF1 and breast cancer.Case presentation
A 54-year-old woman with a diagnosis of NF1 according
to the National Institutes of Health criteria [8] was re-
ferred to the Breast Service of the Hospital Universitário
Antônio Pedro of Universidade Federal Fluminense by the
Oral Diagnosis Service from the same institution with the
complaint of a “secretion from a mass in her left breast”.
The patient reported that she delayed consulting a phys-
ician because she thought the mass was a manifestation of
NF1. She was post-menopausal and had no family history
of breast or ovarian cancer.
On physical examination, we observed thousands of
neurofibromas all over her body, including both breasts
(Figure 1). Left breast palpation revealed a large, tenderis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Clinical aspect of the patient before mastectomy.
Photograph showing the high number of skin neurofibromas. Note
that the left breast is enlarged.
Figure 2 Radiological aspect of the digital mammogram before
surgery. Mammogram illustrating the difficulty in identifying the
tumor mass due to the high number of skin neurofibromas.
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in diameter. Ipsilateral enlarged axillary lymph nodes were
also palpated. Identification of the nipple-areolar complex
was difficult because of the extension of her neurofibro-
mas. At consultation, a needle core-biopsy was performed,
and histopathological analysis revealed a grade 1 ductal
carcinoma in situ. Digital mammograms were performed,
but they were very difficult to interpret due to the exten-
sion of the cutaneous lesions. A large breast density asso-
ciated with diffuse microcalcification was identified
(Figure 2).
The clinical decision was to precede with a modified
radical mastectomy and axillary clearance of levels I and
II, because of the size of the mass. The surgical procedure
was uneventful, with the skin incision contouring the
neurofibromas. Of note, the skin flaps dissection showed
some large vessels irrigating the skin, which necessitated
great care when raising the flaps. Dissected axillary lymph
nodes were large and soft. The healing process was
normal, and the patient had a favorable evolution.
The histopathological analysis of the surgical specimen
showed extensive high-grade ductal carcinoma in situ,
comedo type, 10 cm in diameter and located in all breast
quadrants, associated with an invasive ductal carcinoma
measuring 0.4 cm. Mastectomy margins were free of dis-
ease. Histopathological analysis confirmed that the nodu-
lar cutaneous lesions were neurofibromas. Forty lymph
nodes were isolated and showed only inflammatory reac-
tion. Immunohistochemistry analyses revealed tumor cells
negative for estrogen receptor (ER), progesterone receptor
(PR), pan-cytokeratin (pan-CK), S100, vimentin and
epithelial membrane antigen (EMA). Ki-67 was positive
in 25-50% of tumor cells; Her2/neu was also positive
(2+/3+). Fluorescence in situ hybridization (FISH) was in-
conclusive due to exhaustion of the invasive componentof the tumor in the paraffin block. There was a small inva-
sion of the pectoralis fascia in the upper inner quadrant,
though no invasive tumor was found in the breast directly
over it. Final pTNM staging was pT1N0M0.
The patient completed the chemotherapy treatment
(cyclophosphamide, methotrexate and fluorouracil; six cy-
cles), and is currently on a course of radiotherapy because
of the size of the tumor. The medical oncologist decided
on chemotherapy based on the size of the tumor mass,
even with an invasive portion of less than one centimeter
because of the aggressive biology of the tumor observed
by immunohistochemistry and also because of the worse
prognosis of breast cancer in NF1 patients reported in
the literature.
Discussion
Although digital mammography is the gold standard for
screening for early stage breast cancer, in this paper we
highlight the challenge in interpreting images of a large
breast carcinoma in an NF1 patient due to the high num-
ber of skin neurofibromas. Physical examination of this
patient was also somewhat impaired because of the
amount of cutaneous lesions. The difficultly in detecting
breast cancer in NF1 individuals with numerous skin
neurofibromas has been reported previously [4,9,10]. NF1
can obscure or delay the identification of breast lesions
not only because skin neurofibromas can mask the signs
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cians may mistakenly consider a breast mass to be a mani-
festation of the primary disease [11].
The first report of an association between NF1 and
breast cancer was published in 1972 [12]. Several other
clinical cases of NF1 patients with breast cancer were
subsequently presented in the literature [4,9-11,13-17].
Because breast cancer is a common tumor in the general
female population, the exact relationship between NF1
and breast cancer has been debated. To date, the study
with the largest cohort of NF1 individuals (n = 448) that
investigated the prevalence of breast cancer, as well as
other types of cancer, showed that the risk of breast can-
cer was significantly higher in NF1 patients younger
than 50 years of age than in the general population [5].
Sharif et al. [6] identified 14 cases of breast cancer
within a cohort of 304 NF1 women older than 20 years,
which represented a 3.5-fold risk of breast cancer in as-
sociation with NF1. The same study calculated a 4.9-fold
risk of developing breast cancer up to age of 50, repre-
senting an 8.4% cumulative risk of developing breast
cancer compared with the risk in the general population
of 2%. In a cohort of 126 patients, Madanikia et al. [7],
in a retrospective study with 506 NF1 patients, identified
four cases of breast cancer, and found a trend for an al-
most 3-fold increase in the risk of breast cancer in
women with NF1 who were <50 years old compared
with age-matched unadjusted incidence rates.
The data showing a high prevalence and a possible earl-
ier onset of breast cancer in NF1 individuals have import-
ant implications on screening [5]. Breast cancer screening
guidelines have been delineated for the general population
and for women with known genetic risk factors for breast
cancer (i.e. BRCA1 and PTEN syndromes) to decrease
mortality through early diagnosis; however, there are cur-
rently no such guidelines for NF1 patients [7].
A study of over 1,000 NF1 individuals found an inci-
dence of breast cancer mortality in NF1 females of ap-
proximately 3.5-fold that of the general population [18].
This finding suggests that not only is there an increased
risk and earlier onset of breast cancer in women with
NF1, but also a worse prognosis associated with the dis-
ease. As occurred in our patient, most of the cases of
breast cancer in NF1 individuals are diagnosed at an ad-
vanced stage with a T score greater than 2 [9,13]. There-
fore, the worse prognosis of breast cancer in NF1 may
not be a characteristic of the disease itself, but may re-
sult from late-stage diagnosis due to the presence of skin
neurofibromas, which hinder its identification, or due to
the delay in seeking medical care by patients who think
the breast mass is a neurofibroma. The most common
histopathological type of breast cancer in NF1, as well as
in the general population, is infiltrating ductal carcinoma
[7], as observed in our case.The scientific data support a real association between
breast cancer and NF1. With regard to this, various au-
thors have suggested different mechanisms supporting the
relationship between NF1 and breast cancer. One of the
implicated oncogenic events in breast cancer is the over-
expression of Ras, which occurs in up to 60% of all cases
and exerts several effects including perturbed cytoskeletal
structure, decreased cell survival and increased apoptosis
[19]. Neurofibromin, the protein product of NF1 gene,
which is located on chromosome 17q11.2, functions as a
negative regulator of the Ras pathway, interacting with
Ras and converting active Ras-GTP to its inactive form,
Ras-GDP. The NF1 gene acts in accordance with the
Knudson two-hit hypothesis: in NF1-related tumors, bial-
lelic inactivation of the NF1 gene results in complete loss
of functional neurofibromin activity [13]. In addition to
upregulation of Ras, absence of neurofibromin expression
has been observed in breast cell lines [20], suggesting
overlapping etiologies [13]. However, it is not known
whether the lack of neurofibromin is a primary or a sec-
ondary event in breast cancer tumorigenesis. Interestingly,
around 30% of sporadic breast cancers in humans lack at
least one copy of NF1 gene [15].
Mutations of the tumor suppressor genes BRCA1 and
BRCA2 are known to be associated with different patterns
of hereditary breast and ovarian cancer [13]. Because
BRCA1, like NF1, is located on human chromosome 17q,
it has been suggested that an interaction could exist be-
tween these two genes [6]. While it is probable that some
individuals reported in the literature carried mutations in
both BRCA1 and NF1 genes, there is a scarcity of reports
of germline mutations in both genes in the same individ-
ual. To the best of our knowledge, Campos et al. [13] were
the only group to report a family with individuals with
diagnosis of NF1 and breast cancer who were carriers of
both BRCA1 and NF1 mutations. They concluded that
the concurrence of NF1 and breast cancer was probably
due to the simultaneous existence of two cancer-
predisposing conditions.
Conclusion
In conclusion, it is important that patients and physicians
are aware of the increased risk of breast cancer in the NF1
subset. For early detection, it seems that the best practice
guidelines used to screen women in the general population
are not sufficient for NF1 patients. Published data justify
earlier screening programs designed specifically for this
group, including annual physical examination by a breast
specialist. The problems presented by interpreting mam-
mograms from NF1 patients highlight a need for more in-
tensive non-mammographic breast imaging studies in
patients with high numbers of neurofibromas. Examples of
these include ultrasound and magnetic resonance imaging.
The sensitivity of which are unlikely to be affected by
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an absence of radiation-related side effects. It is clear that
more studies are necessary to clarify the relationship be-
tween these two diseases and to develop specific screening
guidelines if earlier diagnosis and decreased morbidity and
mortality are to be achieved in women with NF1 and
breast cancer.
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